Cutera, Inc. (NASDAQ:CUTR – Get Free Report) saw a significant decrease in short interest during the month of August. As of August 31st, there was short interest totalling 3,930,000 shares, a decrease of 10.3% from the August 15th total of 4,380,000 shares. Based on an average daily trading volume, of 556,900 shares, the short-interest ratio is currently 7.1 days.
Cutera Stock Performance
CUTR stock traded down $0.01 during midday trading on Tuesday, reaching $0.75. 168,494 shares of the company traded hands, compared to its average volume of 1,056,983. The business has a 50 day moving average of $1.04 and a 200-day moving average of $1.62. Cutera has a 52-week low of $0.65 and a 52-week high of $9.45. The firm has a market capitalization of $15.07 million, a price-to-earnings ratio of -0.10 and a beta of 1.32.
Cutera (NASDAQ:CUTR – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical device company reported ($1.23) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.32. The business had revenue of $34.38 million during the quarter, compared to analysts’ expectations of $39.47 million. Research analysts anticipate that Cutera will post -5.13 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on the company. Stephens dropped their price target on Cutera from $10.00 to $5.00 and set an “overweight” rating for the company in a research note on Friday, August 9th. Piper Sandler restated a “neutral” rating and set a $1.00 price objective (down from $3.00) on shares of Cutera in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cutera has an average rating of “Hold” and an average price target of $5.33.
View Our Latest Research Report on Cutera
Cutera Company Profile
Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for deep dermal remodeling; truFlex, a bio-electrical muscle stimulation device to treat patients at all fitness levels; and excel V+, a vascular and benign pigmented lesion treatment platform.
Further Reading
- Five stocks we like better than Cutera
- What is a Special Dividend?
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- 3 Small Caps With Big Return Potential
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.